Pipeline
| Program | Therapeutic Area | Core Indications | Mode of Action |
|---|---|---|---|
| AKT-101 (optioned) | Immune-Stimulant | Prevention of secondary respiratory infections in dogs and cats | Oral bacterial lysate triggers non-specific immune response strengthening immune system against infections. |
| AKT-201 (internal) | Pain and Inflammation | Feline Gingivostomatitis + Equine Navicular Dx | Potent TRPV1 agonist defunctionalizes targeted nerves at site of injection interrupting pain signaling (non-opioid) |
| Not Assigned (in negotiation) | CNS | Epileptic Seizures (K9) | Benzodiazepine used for control of seizure episodes |
| Not Assigned (option pending) | Inflammation | Osteoarthritis Pain and Inflammation | PAI-1 inhibitor. New modality for chronic musculoskeletal pain, and neuropathic pain control |
| Not Assigned (option pending) | CNS | Fear and Anxiety + Neuropathic Pain | 5HT1 agonist targeting central system (mood, anxiety and stress responses) |
| Not Assigned (option pending) | Urinary | Prevention of Urinary Tract Infections in cats with recurring UTIs | Immuno-modulating bacterial Lysate designed to support immune system responses to urinary tract pathogens |
Details available to interested investors under CDA (separate presentation)